---

---

therapeutics   tags : Application   

save search

---

Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
Published: 2024-04-08 (Crawled : 09:00) - biospace.com/
CALT | News | $18.3 -2.35% -2.4% 6.1K |

Health Technology

| -18.4% | O: -1.06% H: 3.5% C: 0.51%
patent cancer treatment for application

---

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Published: 2024-04-02 (Crawled : 11:00) - globenewswire.com
AUTL | $4.8 -0.83% -0.83% 1.2M |

Health Technology

| -20.72% | O: -7.83% H: 3.27% C: -2.48%
authorization application leukemia therapeutics

---

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.385 -0.36% -0.36% 46K |

Health Technology

| 2.17% | O: 8.7% H: 3.33% C: -8.67%
ctim-76 application therapeutics

---

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
Published: 2024-03-19 (Crawled : 12:00) - globenewswire.com
CLPT | $5.39 -2.53% -2.6% 87K |

Health Technology

| -21.07% | O: 0.0% H: 0.99% C: -1.27%
fda license treatment application therapeutics submission

---

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
TVTX | $5.805 -3.09% -3.19% 970K |

Health Technology

| -30.83% | O: -0.81% H: 1.51% C: -6.98%
filspari nephropathy drug approval food treatment application therapeutics

---

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -3.17% | O: 1.17% H: 0.0% C: 0.0%
lung drug cancer treatment application therapeutics

---

CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Published: 2024-03-04 (Crawled : 13:00) - globenewswire.com
CBAY | $32.48 0.03% 8.4M |

Health Technology

| 0.68% | O: -0.03% H: 0.19% C: -0.19%
review authorization treatment application

---

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
SWTX | News | $42.48 -3.7% -3.84% 810K |

Health Technology

| -14.19% | O: 0.49% H: 0.12% C: -2.95%
fda drug children treatment application therapeutics submission

---

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SWTX | News | $42.48 -3.7% -3.84% 810K |

Health Technology

| -9.96% | O: 2.2% H: 1.21% C: -0.85%
tumors authorization treatment application therapeutics

---

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
APLT A | $4.74 -1.86% -1.9% 720K |

Health Technology

| -7.71% | O: 44.8% H: 16.21% C: -8.42%
fda drug review treatment application therapeutics

---

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
RNAZ | $0.5195 3.59% 3.46% 270K |

Professional, Scientific, and T...

| -26.36% | O: 1.87% H: 0.0% C: -1.84%
patent agonist publication application therapeutics

---

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA®
Published: 2024-02-19 (Crawled : 17:00) - biospace.com/
OCUL | News | $5.86 -22.69% -29.35% 6.1M |

Health Technology

| Email alert Add to watchlist
dextenza drug health sciences application therapeutics

---

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
Published: 2024-02-19 (Crawled : 14:00) - prnewswire.com
OCUL | News | $5.86 -22.69% -29.35% 6.1M |

Health Technology

| Email alert Add to watchlist
dextenza drug health ocular treatment sciences application therapeutics

---

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
TENX | $3.67 2.23% 2.18% 21K |

Health Technology

| -57.8% | O: 132.91% H: 5.66% C: -43.62%
patent application grants therapeutics

---

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
Published: 2024-02-06 (Crawled : 13:00) - globenewswire.com
APRE | $5.73 -1.29% 870 |

Health Technology

| -10.82% | O: 3.2% H: 9.6% C: 8.49%
apr-1051 application therapeutics submission

---

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
BTAI | $2.56 -1.16% -1.17% 240K |

Health Technology

| -16.67% | O: 9.48% H: 15.37% C: 10.75%
patent disease alzheimer’s application therapeutics

---

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
Published: 2024-02-01 (Crawled : 12:30) - globenewswire.com
ABEO | $7.55 -4.79% -5.03% 250K |

Health Technology

| 70.55% | O: -1.13% H: 0.0% C: 0.0%
license update application therapeutics

---

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
Published: 2024-01-29 (Crawled : 15:30) - biospace.com/
CYTH | $1.22 0.83% 0.82% 30K |

Professional, Scientific, and T...

| -29.82% | O: 6.43% H: 1.58% C: -2.75%
patent disease alzheimer’s treatment application therapeutics

---

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder
Published: 2024-01-25 (Crawled : 11:00) - globenewswire.com
UTHR | $237.16 0.79% 0.78% 480K |

Health Technology

| 7.54% | O: 0.54% H: 1.08% C: -0.31%
LQDA M | $13.81 -0.36% -0.36% 670K |

Health Technology

| 14.51% | O: -7.63% H: 12.84% C: 7.45%
drug corporation update application

---

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
Published: 2024-01-24 (Crawled : 14:00) - globenewswire.com
CYTO | $1.48 -7.95% 25K |

Manufacturing

| -28.57% | O: 21.43% H: 1.52% C: -10.59%
patent cancer treatment application therapeutics

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---